Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Multicenter Phase ◽

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3583 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3583-3583 ◽

Cited By ~ 22

Author(s):

A. L. A. Fields ◽

D. A. Rinaldi ◽

C. A. Henderson ◽

C. J. Germond ◽

L. Chu ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Second Line ◽

Open Label ◽

Second Line Therapy ◽

Multicenter Phase ◽

Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

International Journal of Clinical Oncology ◽

10.1007/s10147-019-01473-3 ◽

2019 ◽

Vol 24 (10) ◽

pp. 1223-1230 ◽

Cited By ~ 2

Author(s):

Nobuaki Suzuki ◽

Shoichi Hazama ◽

Takeshi Nagasaka ◽

Hiroaki Tanioka ◽

Yasuo Iwamoto ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Multicenter Phase ◽

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

Annals of Oncology ◽

10.1093/annonc/mdw412 ◽

2016 ◽

Vol 27 (12) ◽

pp. 2216-2224 ◽

Cited By ~ 14

Author(s):

M. Moore ◽

S. Gill ◽

T. Asmis ◽

S. Berry ◽

R. Burkes ◽

...

Keyword(s):

Colorectal Cancer ◽

Disease Progression ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

First Line ◽

Second Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii

Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3255-3 ◽

2017 ◽

Vol 79 (3) ◽

pp. 579-585 ◽

Cited By ~ 8

Author(s):

Hidekazu Kuramochi ◽

Masayuki Ando ◽

Michio Itabashi ◽

Go Nakajima ◽

Kazuyuki Kawakami ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Previously Treated

Abstract CT124: A phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab

10.1158/1538-7445.am2016-ct124 ◽

2016 ◽

Author(s):

Go Nakajima ◽

Hidekazu Kuramochi ◽

Masayuki Ando ◽

Michio Itabashi ◽

Kazuyuki Kawakami ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Previously Treated

Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial

Annals of Oncology ◽

10.1093/annonc/mdz421.036 ◽

2019 ◽

Vol 30 ◽

pp. ix39

Author(s):

J.L. Zhu ◽

S. Li ◽

C. Zhu

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Trial ◽

Second Line ◽

Efficacy And Safety ◽

Second Line Therapy ◽

Multicenter Phase ◽

A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-018-3568-x ◽

2018 ◽

Vol 81 (6) ◽

pp. 1035-1041 ◽

Cited By ~ 1

Author(s):

Chu Matsuda ◽

Michitaka Honda ◽

Chihiro Tanaka ◽

Ken Kondo ◽

Takao Takahashi ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line Therapy

Cancer Research and Treatment ◽

10.4143/crt.2006.38.4.201 ◽

2006 ◽

Vol 38 (4) ◽

pp. 201

Author(s):

Duk-Joo Lee ◽

Ho-Suk Oh ◽

Jung-Hye Choi ◽

Young-Yeul Lee ◽

In-Soon Kim ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil

Annals of Oncology ◽

10.1093/annonc/mdn002 ◽

2008 ◽

Vol 19 (6) ◽

pp. 1154-1159 ◽

Cited By ~ 9

Author(s):

C. Qvortrup ◽

M. Yilmaz ◽

D. Ogreid ◽

A. Berglund ◽

L. Balteskard ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Short Time

PEPCOL : a GERCOR randomized phase II study of nanoliposomal irinotecan PEP 02 ( MM ‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

Cancer Medicine ◽

10.1002/cam4.635 ◽

2016 ◽

Vol 5 (4) ◽

pp. 676-683 ◽

Cited By ~ 29

Author(s):

Benoist Chibaudel ◽

Frédérique Maindrault‐Gœbel ◽

Jean‐Baptiste Bachet ◽

Christophe Louvet ◽

Ahmed Khalil ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii ◽

Nanoliposomal Irinotecan